Therapeutic targeting of CD36 after intracerebral hemorrhage
脑出血后 CD36 的治疗靶向
基本信息
- 批准号:8432013
- 负责人:
- 金额:$ 18.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-03-01 至 2015-02-28
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcuteAddressAmericanBiochemicalBlood ClotBlood VesselsBlood coagulationBrainBrain hemorrhageCCAAT-Enhancer-Binding ProteinsCD36 geneCerebral hemisphere hemorrhageClinicalClinical ManagementCoagulation ProcessCurcuminDataDeteriorationDevelopmentDiabetes MellitusDoseErythrocytesGeneticGoalsHematomaHemorrhageHumanHypertensionIncidenceInterventionKnowledgeLaboratoriesLesionLocationMediatingMediator of activation proteinMedicalMicrogliaModelingMolecularMolecular WeightMorbidity - disease rateMusNervous System TraumaNeurologicNeurological outcomeOperative Surgical ProceduresOutcomePathway interactionsPatientsPatternPhagocytosisPharmacologic SubstanceResearchResolutionRisk FactorsRodentRoleRuptureSR-B proteinsSerumSpicesStrokeTestingTherapeuticaging populationbasebrain tissueclinical careclinical practicedemographicsimprovedmortalityneuroimagingnovelnovel therapeuticspre-clinicaltherapeutic targettranscription factor
项目摘要
DESCRIPTION (provided by applicant): Intracerebral hemorrhage (ICH), the most common form of hemorrhagic stroke, accounts for up to 15% of all strokes, with 37,000-52,400 Americans suffering an ICH annually. ICH has the highest acute mortality and the worst long-term neurological outcomes of all types of stroke. ICH is caused by a ruptured blood vessel within the brain, leading to the formation of a space occupying hematoma. Hematoma volume is clinically associated with neurological deterioration and higher mortality; however, many ICH patients are poor surgical candidates and/or present with an unfavorable size/location of the lesion, restricting the utility of neurosurgical intervention. Furthermore, efficacious medical treatment options to promote hematoma clearance are lacking, presenting a critical barrier to clinical practice. Our long-term objective is to identify the molecular and cellular pathways which
contribute to clot resolution after ICH. This knowledge will provide a framework for pharmaceutical development to improve patient outcomes after ICH. Our pilot data suggest the curry spice, curcumin, promotes hematoma resolution after ICH and may therefore represent a novel and safe treatment option. Specific Aim 1 will test the hypothesis that CD36 mediates curcumin-induced hematoma clearance after ICH. Specific Aim 2 will test the hypothesis that C/EBP-¿ mediates curcumin-induced CD36 expression and hematoma resolution after ICH. Together, the proposed studies will elucidate the molecular and cellular mechanisms which underlie the ability of curcumin to promote hematoma resolution. The results of these studies will provide a framework for pharmaceutical development targeting C/EBP-¿ and/or CD36 to improve clinical outcomes after ICH.
描述(由申请人提供):脑出血(ICH)是出血性卒中的最常见形式,占所有卒中的15%,每年有37,000 - 52,400名美国人患有ICH。在所有类型的卒中中,ICH的急性死亡率最高,长期神经系统结局最差。脑出血是由脑内血管破裂引起的,导致形成占位性血肿。血肿体积在临床上与神经功能恶化和较高的死亡率相关;然而,许多ICH患者是不佳的手术候选者和/或存在不利的病变大小/位置,限制了神经外科干预的效用。此外,缺乏促进血肿清除的有效药物治疗选择,这对临床实践构成了关键障碍。我们的长期目标是确定分子和细胞途径,
有助于ICH后凝块消退。这些知识将为药物开发提供一个框架,以改善ICH后的患者结局。我们的试验数据表明,咖喱香料,姜黄素,促进脑出血后血肿的解决,因此可能代表一种新的和安全的治疗选择。具体目标1将检验CD 36介导姜黄素诱导的ICH后血肿清除的假设。具体目标2将检验C/EBP-â介导姜黄素诱导的CD 36表达和ICH后血肿消退的假设。总之,拟议的研究将阐明姜黄素促进血肿消退能力的分子和细胞机制。这些研究的结果将为靶向C/EBP-1和/或CD 36的药物开发提供框架,以改善ICH后的临床结局。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KRISHNAN M. DHANDAPANI其他文献
KRISHNAN M. DHANDAPANI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KRISHNAN M. DHANDAPANI', 18)}}的其他基金
Immunometabolic regulation after CNS injury
中枢神经系统损伤后的免疫代谢调节
- 批准号:
10737334 - 财政年份:2023
- 资助金额:
$ 18.09万 - 项目类别:
Remote ischemic Conditioning Promotes Cerebrovascular Recovery after Intracerebral Hemorrhage
远程缺血调理促进脑出血后脑血管恢复
- 批准号:
10676330 - 财政年份:2020
- 资助金额:
$ 18.09万 - 项目类别:
Remote ischemic Conditioning Promotes Cerebrovascular Recovery after Intracerebral Hemorrhage
远程缺血调理促进脑出血后脑血管恢复
- 批准号:
10240740 - 财政年份:2020
- 资助金额:
$ 18.09万 - 项目类别:
Remote ischemic Conditioning Promotes Cerebrovascular Recovery after Intracerebral Hemorrhage
远程缺血调理促进脑出血后脑血管恢复
- 批准号:
10459588 - 财政年份:2020
- 资助金额:
$ 18.09万 - 项目类别:
Remote ischemic Conditioning Promotes Cerebrovascular Recovery after Intracerebral Hemorrhage
远程缺血调理促进脑出血后脑血管恢复
- 批准号:
10035049 - 财政年份:2020
- 资助金额:
$ 18.09万 - 项目类别:
Therapeutic targeting of CD36 after intracerebral hemorrhage
脑出血后 CD36 的治疗靶向
- 批准号:
8303510 - 财政年份:2012
- 资助金额:
$ 18.09万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 18.09万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 18.09万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 18.09万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 18.09万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 18.09万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 18.09万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 18.09万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 18.09万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 18.09万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 18.09万 - 项目类别:
Operating Grants